创新药大反攻 港股创新药ETF盘中价再创历史新高

Core Viewpoint - The Hong Kong stock market is experiencing a significant rise, particularly in the innovative drug sector, with the largest innovative drug ETF (513120) reaching a historical high and attracting substantial capital inflow [1][2] Group 1: Market Performance - The Hong Kong innovative drug ETF (513120) saw an intraday increase of over 3%, achieving a new historical price high [1] - The ETF's trading volume exceeded 9 billion yuan, making it the most actively traded pharmaceutical ETF in the market [1] - Over the past month, the ETF has attracted a net capital inflow of over 1.1 billion yuan, with an average daily trading volume of 6.8 billion yuan [1] - The ETF's total size has surpassed 13.6 billion yuan, ranking it as the largest and most liquid innovative drug product in the market [1] - The ETF has delivered a one-year return of 101.62%, making it the top-performing international equity fund in the market [1] Group 2: Investment Advantages - The innovative drug ETF (513120) is favored by investors due to its scale, liquidity, and performance advantages, as well as the purity of its underlying index, the China Hong Kong Innovative Drug Index (CNY) [2] - The annualized return of the Hong Kong innovative drug index has significantly outperformed other pharmaceutical indices since 2019, with lower volatility, resulting in a superior Sharpe ratio [1][2] - The top ten samples in the Hong Kong innovative drug ETF represent a high degree of relevance for innovative drug investments [2] - Chinese pharmaceutical companies have made significant strides in overseas License-out transactions, showcasing the global competitiveness of Chinese innovative drug research and development [2] - With supportive policies and advancements in AI, the innovative drug sector is expected to enter a harvest period around 2025-2026 [2]